Περίληψη:
Purpose. To evaluate the outcome and the prognosis of patients with
ovarian germ cell malignancies who were treated with platinum-based
chemotherapy immediately after initial surgery.
Methods. We conducted a retrospective review of patients with ovarian
germ cell tumors who were referred for consideration of treatment to the
Departments of Medical Oncology participating in the Hellenic
Cooperative Oncology Group.
Results. Over a 10-year period 53 patients were included in our study.
There were 13 patients with dysgerminoma and 40 patients with
nondysgerminomatous tumors. Forty percent of patients underwent complete
resection of their tumors. Platinum-based chemotherapy consisted
primarily of cisplatin, vinblastine, and bleomycin (PVB) in 9 patients;
bleomycin, etoposide, and cisplatin (BEP) in 15 patients; and bleomycin,
etoposide, and carboplatin (BEC) in 25 patients. With a median follow-up
of 39 months, 5 patients developed progressive disease and died of their
tumor and 1 patient died of bleomycin-induced lung toxicity with no
evidence of active tumor. The 5-year overall survival was 100% for
patients with dysgerminoma and 85% for patients with
nondysgerminomatous tumors. Eighty percent of patients with advanced
nondysgerminomatous tumors and residual disease after surgery remain
disease free.
Conclusion. With this study we confirm that patients with ovarian germ
cell malignancies have a favorable outcome when treated with
platinum-based chemotherapy. (C) 1998 Academic Press.
Συγγραφείς:
Dimopoulos, MA
Papadopoulou, M
Andreopoulou, E and
Papadimitriou, C
Pavlidis, N
Aravantinos, G
Aspropotamitis,
A
Anagnostopoulos, A
Fountzilas, G
Michalas, S and
Pectacides, D
